渝三峽A(000565.SZ):投入4091.37萬元認購北陸藥業可轉債
格隆匯12月8日丨渝三峽A(000565.SZ)公佈,2020年12月3日,公司參股公司北陸藥業(300016.SZ)披露了《向不特定對象發行可轉換公司債券發行公告》,公司作為北陸藥業股東,享有北陸藥業發行的可轉債的優先配售權。
截至目前,公司持有北陸藥業無限售流通股份4046.45萬股,佔北陸藥業總股本的8.18%。根據北陸藥業上述發行公告,公司於2020年12月7日通過深交所交易系統優先認購北陸藥業可轉債40.9137萬張,每張面值為人民幣100元,共計投入資金人民幣4091.37萬元。
2020年12月8日,北陸藥業披露了《向不特定對象發行可轉換公司債券網上發行中籤率及優先配售結果公告》確定了發行申購結果。
公司此次投資資金來源為自有資金,公司根據持有目的和《企業會計準則》規定將此次認購的可轉債計入“交易性金融資產”科目核算。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.